|
cfDNA extraction method
|
Cobas cfDNA sample preparation kit (Roche)
|
QIAamp Circulating Nucleic Acid Kit (Qiagen)
| |
|---|
|
Variant analysis method
|
Cobas® EGFR Mutation Test v2 (Roche)
|
Capture SureSelect (Agilent), MiSeq (Illumina)
|
QX200 Droplet Digital PCR System (Bio-rad)
|
Ampliseq 50 gene hotspot panel, Ion Proton (LifeTechnologies)
|
Therascreen® EGFR Plasma RGQ PCR Kit (Qiagen)
|
OncoBEAM® RAS CRC IVD KIT (Sysmex-Inostics)
|
|---|
|
Reference laboratory code
|
1, 2
|
2
|
3°, 4
|
4
|
5
|
5
|
1–5
|
|
Sample
|
# errors/# genotypes analyzed (error rate in %)
|
|
A
|
/
|
1/1 (100.0%)
|
0/2 (0.0%)
|
0/1 (0.0%)
|
/
|
0/1 (0.0%)
|
1/5 (20.0%)
|
|
B
|
/
|
1/1 (100.0%)
|
0/2 (0.0%)
|
1/1 (100.0%)
|
/
|
0/1 (0.0%)
|
2/5 (40.0%)
|
|
C
|
/
|
1/1 (100.0%)
|
0/1 (0.0%)
|
0/1 (0.0%)
|
/
|
0/1 (0.0%)
|
1/4 (25.0%)
|
|
D
|
/
|
1/1 (100.0%)
|
1/1 (100.0%)
|
1/1 (100.0%)
|
/
|
0/1 (0.0%)
|
3/4 (75.0%)
|
|
E
|
/
|
0/1 (0.0%)
|
0/2 (0.0%)
|
0/1 (0.0%)
|
/
|
0/1 (0.0%)
|
0/5 (0.0%)
|
|
F
|
0/2 (0.0%)
|
1/1 (100.0%)
|
0/2 (0.0%)
|
0/1 (0.0%)
|
0/1 (0.0%)
|
/
|
1/7 (14.3%)
|
|
G
|
0/2 (0.0%)
|
1/1 (100.0%)
|
0/2 (0.0%)
|
0/1 (0.0%)
|
0/1 (0.0%)
|
/
|
1/7 (14.3%)
|
|
H
|
0/2 (0.0%)
|
1/1 (100.0%)
|
0/2 (0.0%)
|
1/1 (100.0%)
|
0/1 (0.0%)
|
/
|
2/7 (28.6%)
|
|
I
|
1/2 (50.0%)
|
1/1 (100.0%)
|
1/2 (50.0%)
|
1/1 (100.0%)
|
0/1 (0.0%)
|
/
|
4/7 (57.1%)
|
|
J
|
0/2 (0.0%)
|
0/1 (0.0%)
|
0/2 (0.0%)
|
0/1 (0.0%)
|
0/1 (0.0%)
|
/
|
0/7 (0.0%)
|
|
A-J
|
1/10 (10.0%)
|
8/10 (80.0%)
|
2/18 (11.1%)
|
4/10 (40.0%)
|
0/5 (0.0%)
|
0/5 (0.0%)
|
15/58 (25.9%)
|
- /, Sample not tested because gene not included in validated methodology. °Reference laboratory n°3 did not test NRAS status. Reference sequence at time of scoring: EGFR: NM_005228.4 or LRG_304t1; KRAS: NM_033360.3 or NM_004985.4; NRAS: NM_002524.4 or LRG_92t1
